Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Michael Diem Joins Medgenics

Executive Summary

The genomic medicine company, Medgenics Inc., has appointed Michael Diem, former head of corporate strategy and corporate development at AstraZeneca PLC, senior vice president of business and corporate development.

You may also be interested in...

Big Pharma's Bad Attitude: Are CEOs Giving Industry A Bad Rep?

Big pharma has been big news recently, with politicians and the general public wading into industry debates on drug pricing, profit-making and trial transparency under the gleeful eye of the international press. Unsurprisingly, pharma has come out on the losing side of these debates, its scientific accomplishments forced into the shadows by the actions of executives such as Martin Shkreli, who have ensured that the spotlight is firmly on the people behind the businesses rather than the products they manufacture.

Pfizer's Martine J. George joins GarmaMabs

GarmaMabs Pharma has appointed Martine J. George an independent board member.

Mylan Appoints Kenneth Parks CFO

Mylan has appointed Kenneth Parks chief financial officer (CFO).





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts